RGLS - Regulus Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.32
+0.08 (+6.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.24
Open1.28
Bid1.32 x 1400
Ask1.43 x 900
Day's Range1.25 - 1.44
52 Week Range1.04 - 17.28
Volume307,861
Avg. Volume469,349
Market Cap11.55M
Beta (3Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-7.16
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.13
Trade prices are not sourced from all markets
  • Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
    Zacks7 days ago

    Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 24.36% and -10.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press7 days ago

    Regulus: 3Q Earnings Snapshot

    The San Diego-based company said it had a loss of $1.18 per share. The biopharmaceutical company posted revenue of $18,000 in the period. In the final minutes of trading on Thursday, the company's shares ...

  • Regulus Reports Third Quarter 2018 Financial Results and Recent Updates
    PR Newswire7 days ago

    Regulus Reports Third Quarter 2018 Financial Results and Recent Updates

    $47 Million Restructured Sanofi Collaboration Executed Initiated New Chronic Mouse Toxicity Study for RGLS4326; Data Anticipated in Q1 2019 LA JOLLA, Calif. , Nov. 8, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Announces Successful Restructuring of Sanofi Collaboration
    PR Newswire10 days ago

    Regulus Announces Successful Restructuring of Sanofi Collaboration

    Sanofi Will Assume Development of RG-012 for Alport syndrome LA JOLLA, Calif. , Nov. 6, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery ...

  • Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018
    PR Newswire21 days ago

    Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 25, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • ACCESSWIRE23 days ago

    3 Healthcare Stocks To Watch On Tuesday

    Healthcare stocks have helped during times like these. Three healthcare stocks to watch this week include Premier Health Group, Inc. (PHGRF)(PHGI.CN), Neovasc Inc. (NVCN), and Regulus Therapeutics Inc. (RGLS). Premier Health Group, Inc. (PHGRF)(PHGI.CN), continued to trade higher this week.

  • Benzinga24 days ago

    The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks None of the stocks hit 52-week highs in Monday's session. Down In The Dumps (Biotech stocks hitting 52-week ...

  • Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018
    PR Newswire24 days ago

    Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018

    LA JOLLA, Calif. , Oct. 22, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • Regulus Regains Compliance with NASDAQ Listing Requirements
    PR Newswire28 days ago

    Regulus Regains Compliance with NASDAQ Listing Requirements

    LA JOLLA, Calif. , Oct. 18, 2018 /PRNewswire/ --  Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, ...

  • GlobeNewswirelast month

    Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Regulus Therapeutics Announces Reverse Stock Split
    PR Newswirelast month

    Regulus Therapeutics Announces Reverse Stock Split

    The effective time of the reverse stock split was 5:00 p.m. ET on October 3, 2018.  The Company's shares will begin trading on a split-adjusted basis commencing upon market open on October 4, 2018. "Over the past several months, we have taken steps to reposition Regulus for long term sustainability.

  • Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference
    PR Newswirelast month

    Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference
    PR Newswire2 months ago

    Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference

    Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.  Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field.  Regulus maintains its corporate headquarters in La Jolla, CA.  For more information, please visit http://www.regulusrx.com. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements.

  • Regulus Provides Pipeline Updates
    PR Newswire2 months ago

    Regulus Provides Pipeline Updates

    Hepatitis B virus (HBV) Programs: The Company has identified several microRNA targets that serve as host factors for the virus.  The Company's lead compound directed to one of the host microRNAs has demonstrated sub-nanomolar potency against HBV DNA replication and 95% reduction in HBsAg in in vitro studies.  The Company believes that targeting a host factor in the liver represents a unique mechanism of action for treatment of the virus compared to other programs in development and holds the potential for achieving a functional cure. The Company currently expects to file an IND for the HBV program in the second half of 2019, with the potential of achieving human proof-of-concept in a Phase 1 study. Glioblastoma multiforme (GBM) Program: The Company's lead anti-miR candidate targeting microRNA-10b demonstrated statistically significant improvements in survival as both a monotherapy as well as in combination with temozolamide (TMZ) in an orthotopic GBM animal model.

  • Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?
    Simply Wall St.2 months ago

    Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)?

    The big shareholder groups in Regulus Therapeutics Inc (NASDAQ:RGLS) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning aRead More...

  • ACCESSWIRE3 months ago

    These Biotech Stocks Are Moving Higher in August

    GT Biopharma (GTBP) for example, recently announced that the company has a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota, has brought some attention to the company. Under the terms of the agreement, this Company will supply a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.

  • Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates

    Regulus (RGLS) delivered earnings and revenue surprises of 18.75% and -10.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Regulus: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 13 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for ...

  • Regulus Reports Second Quarter 2018 Financial Results and Recent Updates
    PR Newswire3 months ago

    Regulus Reports Second Quarter 2018 Financial Results and Recent Updates

    Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway Amendment to Term Loan to Provide Additional Interest-Only Period LA JOLLA, Calif. , Aug. 9, 2018 /PRNewswire/ --  Regulus Therapeutics ...

  • Regulus Stock Plunges on Cash Concerns Despite Restructuring
    Zacks4 months ago

    Regulus Stock Plunges on Cash Concerns Despite Restructuring

    Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.

  • Regulus Announces Strategic Update and Corporate Restructuring
    PR Newswire4 months ago

    Regulus Announces Strategic Update and Corporate Restructuring

    Efforts Aimed at Extending Cash Runway to mid-2019 LA JOLLA, Calif. , July 5, 2018 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development ...

  • ACCESSWIRE4 months ago

    Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities

    Stock Research Monitor: RGNX, RGLS, and ABEO LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on XXII sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...